Growth Metrics

Pfizer (PFE) Other Non-Current Assets (2016 - 2025)

Pfizer (PFE) has disclosed Other Non-Current Assets for 17 consecutive years, with $9.3 billion as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Assets fell 11.15% to $9.3 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $9.3 billion, a 11.15% decrease, with the full-year FY2024 number at $9.8 billion, down 21.28% from a year prior.
  • Other Non-Current Assets was $9.3 billion for Q3 2025 at Pfizer, down from $9.5 billion in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $13.2 billion in Q4 2022 to a low of $6.7 billion in Q4 2021.
  • A 5-year average of $9.7 billion and a median of $9.6 billion in 2024 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: soared 71.42% in 2022, then decreased 21.28% in 2024.
  • Pfizer's Other Non-Current Assets stood at $7.7 billion in 2021, then surged by 71.42% to $13.2 billion in 2022, then fell by 5.26% to $12.5 billion in 2023, then dropped by 21.28% to $9.8 billion in 2024, then fell by 5.09% to $9.3 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Other Non-Current Assets are $9.3 billion (Q3 2025), $9.5 billion (Q2 2025), and $9.8 billion (Q1 2025).